Neuronetics, Inc. (NASDAQ: STIM) revealed a significant development in mental healthcare, announcing that Evernorth Health ...

Recognizing how persistent depressive disorder manifests and plays out in the lives of individuals is the first step in ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

The diagnosis of major depressive disorder is based on the patient's self-reported experiences, behavior reported by relatives or friends, and a mental status examination. There is no laboratory ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...

Scientists at the National Center for Supercomputing Applications and the University of Illinois College of Medicine Peoria (UICOMP) were authors of a research paper published in the Journal of ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.